Attributable Mortality of Nosocomial Candidemia, Revisited
The DOI matches its Crossref record; 35 of the 37 references it cites were found in a registry or an index.
Abstract
We reexamined the attributable mortality of nosocomial candidemia 15 years after a retrospective cohort study performed at our hospital demonstrated an attributable mortality of 38%. For all episodes of nosocomial candidemia between 1 July 1997 and 30 June 2001, we matched control patients with case patients by age, sex, date of hospital admission, underlying disease(s), length of time at risk, and surgical procedure(s). We analyzed 108 matched pairs. There were no statistically significant differences in age, sex, underlying disease(s), time at risk, surgical procedure, or vital signs at admission between cases and controls. The crude mortality among case patients was 61% (66 of 108 patients), compared with 12% (13 of 108) among control patients, for an attributable mortality of 49% (95% CI, 38%-60%). Nosocomial candidemia is still associated with an extremely high crude and attributable mortality--much higher than that expected from underlying disease alone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These infections are associated with attributable mortality rates that have ranged from 38% between 1983 and 1986 (46) to 49% in the same institutions between 1997 and 2001 (13).”
In the citing paper
“Attributable mortality of candidiasis was evaluated retrospectively between 1997 and 2001 in 108 matched pairs [12], the crude mortality among case patients was 61% compared with 12% in controls; the resulting ''attributable mortality'' was therefore estimated to be 49%.”
From Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis (2009) · cites this paper as [12]
In the citing paper
“Studies on patients with IC have similarly shown excessive rates of inappropriate initial therapy and even higher mortality than infections caused by bacterial pathogens in the ICU setting.10,14,33,34,[42][43][44][45][46][47]”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [14]
In the citing paper
“Numerous reports have documented the association between inadequate dosing of antifungals in patients with IC and increased length of hospital stay, health care costs, morbidity, and mortality.”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [14]
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
Guidelines for the Prevention of Intravascular Catheter-related Infections
O'Grady, N. P., Alexander, M., Burns, L. A., Dellinger, E. P., Garland, J., Heard, S. O., Lipsett, P. A., Masur, H., Mermel, L. A., Pearson, M. L., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir257 · Cited by 4,699
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
Nosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
Self-citationComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Weinstein, M. P., Towns, M. L., Quartey, S. M., Mirrett, S., Reimer, L. G., Parmigiani, G., & Barth Reller, L. (1997) · Clinical Infectious Diseases · doi:10.1093/clind/24.4.584 · Cited by 1,228
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Practice Guidelines for the Treatment of Candidiasis
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313749 · Cited by 927
Pittet, D. (1994) · JAMA · doi:10.1001/jama.1994.03510440058033 · Cited by 926
Research works printed but not linked: 3
- Harvey, 1987, Archives of Internal Medicine, 147, 2117, 10.1001/archinte.1987.00370120053011 · doi:10.1001/archinte.1987.00370120053011
- Martin, 1989, Annals of Internal Medicine, 110, 9, 10.1059/0003-4819-110-1-9 · doi:10.1059/0003-4819-110-1-9
- O'Grady, 2002, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control, 51, 1
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Self-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
“Invasive candidiasis has a significant impact on patient outcomes, and it has been estimated that the attributable mortality of invasive candidiasis is as high as 47% [11], although many authorities estimate the attributable mortality to be 15%–25% for adults and 10%–15% for neonates and children [12, 13].”
BackgroundReal-Time PCR in Clinical Microbiology: Applications for Routine Laboratory Testing
Espy, M. J., Uhl, J. R., Sloan, L. M., Buckwalter, S. P., Jones, M. F., Vetter, E. A., Yao, J. D. C., Wengenack, N. L., Rosenblatt, J. E., Cockerill, F. R., et al. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.1.165-256.2006 · Cited by 1,318
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217
Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T. (2006) · Clinical Infectious Diseases · doi:10.1086/504810 · Cited by 1,171
“Attributable mortality rates of 49% were also shown among patients with candidemia, compared with uninfected control subjects matched for age, sex, date of hospital admission, underlying diseases, length of time at risk, and type of surgical procedure [5].”
BackgroundConti, H. R., Shen, F., Nayyar, N., Stocum, E., Sun, J. N., Lindemann, M. J., Ho, A. W., Hai, J. H., Yu, J. J., Jung, J. W., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081463 · Cited by 1,024
Horn, D. L., Neofytos, D., Anaissie, E. J., Fishman, J. A., Steinbach, W. J., Olyaei, A. J., Marr, K. A., Pfaller, M. A., Chang, C., & Webster, K. M. (2009) · Clinical Infectious Diseases · doi:10.1086/599039 · Cited by 956
“Attributable mortality has been reported to range from 5% to 71%, and crude mortality rates have been reported to be as high as 81% [11–23].”
BackgroundSelf-citationAn integrated model of the recognition of Candida albicans by the innate immune system
Netea, M. G., Brown, G. D., Kullberg, B. J., & Gow, N. A. R. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1815 · Cited by 946
“1 and 24 cases per 100,000 individuals, and an associated mortality of more than 30”
BackgroundEpidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Self-citationCandida parapsilosis, an Emerging Fungal Pathogen
Trofa, D., Gácser, A., & Nosanchuk, J. D. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00013-08 · Cited by 854
Andes, D. R., Safdar, N., Baddley, J. W., Playford, G., Reboli, A. C., Rex, J. H., Sobel, J. D., Pappas, P. G., Kullberg, B. J., & for the Mycoses Study Group (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis021 · Cited by 793
Zaoutis, T. E., Argon, J., Chu, J., Berlin, J. A., Walsh, T. J., & Feudtner, C. (2005) · Clinical Infectious Diseases · doi:10.1086/496922 · Cited by 784
Nosocomial fungal infections: epidemiology, diagnosis, and treatment
Perlroth, J., Choi, B., & Spellberg, B. (2007) · Medical Mycology · doi:10.1080/13693780701218689 · Cited by 738
Pfaller, M. A., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4419-4431.2004 · Cited by 694
Self-citationGlobal trends in the distribution of Candida species causing candidemia
Guinea, J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12539 · Cited by 680
Hajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M. A., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.4.1519-1527.2004 · Cited by 649
Immune defence against Candida fungal infections
Netea, M. G., Joosten, L. A. B., van der Meer, J. W. M., Kullberg, B.-J., & van de Veerdonk, F. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3897 · Cited by 642
Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis
Pappas, P. G., Rotstein, C. M. F., Betts, R. F., Nucci, M., Talwar, D., De Waele, J. J., Vazquez, J. A., Dupont, B. F., Horn, D. L., Ostrosky-Zeichner, L., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/520980 · Cited by 638
Medically important bacterial-fungal interactions
Peleg, A. Y., Hogan, D. A., & Mylonakis, E. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2313 · Cited by 619
Epidemiology and risk factors for invasive candidiasis
Yapar, N. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s40160 · Cited by 610
Leroy, O., Gangneux, J.-P., Montravers, P., Mira, J.-P., Gouin, F., Sollet, J.-P., Carlet, J., Reynes, J., Rosenheim, M., Regnier, B., et al. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e31819efac0 · Cited by 535
Colombo, A. L., Nucci, M., Park, B. J., Nouér, S. A., Arthington-Skaggs, B., da Matta, D. A., Warnock, D., & Morgan, J. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00773-06 · Cited by 526
Changing patterns and trends in systemic fungal infections
Richardson, M. D. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki218 · Cited by 525
Incidence, characteristics and outcome of ICU-acquired candidemia in India
Chakrabarti, A., Sood, P., Rudramurthy, S. M., Chen, S., Kaur, H., Capoor, M., Chhina, D., Rao, R., Eshwara, V. K., Xess, I., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-014-3603-2 · Cited by 454
Invasive Fungal Pathogens: Current Epidemiological Trends
Pfaller, M. A., Pappas, P. G., & Wingard, J. R. (2006) · Clinical Infectious Diseases · doi:10.1086/504490 · Cited by 448
Self-citationMorgan, J., Meltzer, M. I., Plikaytis, B. D., Sofair, A. N., Huie-White, S., Wilcox, S., Harrison, L. H., Seaberg, E. C., Hajjeh, R. A., & Teutsch, S. M. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502581 · Cited by 437
Igyártó, B. Z., Haley, K., Ortner, D., Bobr, A., Gerami-Nejad, M., Edelson, B. T., Zurawski, S. M., Malissen, B., Zurawski, G., Berman, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.06.005 · Cited by 435
Blot, S. I., Depuydt, P., Annemans, L., Benoit, D., Hoste, E., De Waele, J. J., Decruyenaere, J., Vogelaers, D., Colardyn, F., & Vandewoude, K. H. (2005) · Clinical Infectious Diseases · doi:10.1086/497833 · Cited by 409
Pfaller, M., Neofytos, D., Diekema, D., Azie, N., Meier-Kriesche, H.-U., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.10.003 · Cited by 394
Self-citationKett, D. H., Azoulay, E., Echeverria, P. M., & Vincent, J.-L. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318206c1ca · Cited by 389
Attributable Mortality Rate for Carbapenem-Resistant Klebsiella pneumoniae Bacteremia
Borer, A., Saidel-Odes, L., Riesenberg, K., Eskira, S., Peled, N., Nativ, R., Schlaeffer, F., & Sherf, M. (2009) · Infection Control & Hospital Epidemiology · doi:10.1086/605922 · Cited by 389
Invasive candidiasis as a cause of sepsis in the critically ill patient
Delaloye, J., & Calandra, T. (2014) · Virulence · doi:10.4161/viru.26187 · Cited by 372
Ostrosky-Zeichner, L., Sable, C., Sobel, J., Alexander, B. D., Donowitz, G., Kan, V., Kauffman, C. A., Kett, D., Larsen, R. A., Morrison, V., et al. (2007) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-007-0270-z · Cited by 369
Cleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J., & Chiller, T. M. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis697 · Cited by 366
“0 %) between centres [2, 14, 18, 31] possibly because of lack of standardized criteria.”
Mucosal damage and neutropenia are required for Candida albicans dissemination
Koh, A. Y., Köhler, J. R., Coggshall, K. T., Van Rooijen, N., & Pier, G. B. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.0040035 · Cited by 360
“] and with attributable mortality rates estimated to be between 38% to 49% [”
BackgroundThe evolution of drug resistance in clinical isolates of Candida albicans.
Ford, C. B., Funt, J. M., Abbey, D., Issi, L., Guiducci, C., Martinez, D. A., Delorey, T., Li, B. Y., White, T. C., Cuomo, C., et al. (2015) · eLife · doi:10.7554/elife.00662 · Cited by 348
“…mortality (Pittet et al., 1994; Charles et al., 2003): systemic C. albicans infections are fatal in 42% of cases (Wisplinghoff et al., 2003), despite the use of antifungal therapies, and C. albicans is the fourth most common infection in hospitals (Gudlaugsson et al., 2003; Pappas et al., 2003).”
Falagas, M. E., Roussos, N., & Vardakas, K. Z. (2010) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2010.04.006 · Cited by 346
Tumbarello, M., Posteraro, B., Trecarichi, E. M., Fiori, B., Rossi, M., Porta, R., de Gaetano Donati, K., La Sorda, M., Spanu, T., Fadda, G., et al. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00131-07 · Cited by 343
Forche, A., Alby, K., Schaefer, D., Johnson, A. D., Berman, J., & Bennett, R. J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060110 · Cited by 338
Dadar, M., Tiwari, R., Karthik, K., Chakraborty, S., Shahali, Y., & Dhama, K. (2018) · Microbial Pathogenesis · doi:10.1016/j.micpath.2018.02.028 · Cited by 332
Hachem, R., Hanna, H., Kontoyiannis, D., Jiang, Y., & Raad, I. (2008) · Cancer · doi:10.1002/cncr.23466 · Cited by 331
Genetic and phenotypic intra-species variation in Candida albicans
Hirakawa, M. P., Martinez, D. A., Sakthikumar, S., Anderson, M. Z., Berlin, A., Gujja, S., Zeng, Q., Zisson, E., Wang, J. M., Greenberg, J. M., et al. (2015) · Genome Research · doi:10.1101/gr.174623.114 · Cited by 320
Genomics of the fungal kingdom: Insights into eukaryotic biology
Galagan, J. E., Henn, M. R., Ma, L.-J., Cuomo, C. A., & Birren, B. (2005) · Genome Research · doi:10.1101/gr.3767105 · Cited by 319
Candida sp. Infections in Patients with Diabetes Mellitus
Rodrigues, C., Rodrigues, M., & Henriques, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8010076 · Cited by 315
Immune Recognition of Candida albicans β‐glucan by Dectin‐1
Gow, N. A. R., Netea, M. G., Munro, C. A., Ferwerda, G., Bates, S., Mora‐Montes, H. M., Walker, L., Jansen, T., Jacobs, L., Tsoni, V., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/523110 · Cited by 314
Therapy for fungal diseases: opportunities and priorities
Denning, D. W., & Hope, W. W. (2010) · Trends in Microbiology · doi:10.1016/j.tim.2010.02.004 · Cited by 314
The changing epidemiology of healthcare-associated candidemia over three decades
Diekema, D., Arbefeville, S., Boyken, L., Kroeger, J., & Pfaller, M. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.02.001 · Cited by 309
Self-citationCombination Treatment of Invasive Fungal Infections
Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A., & Ghannoum, M. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.163-194.2005 · Cited by 308
Pachl, J., Svoboda, P., Jacobs, F., Vandewoude, K., van der Hoven, B., Spronk, P., Masterson, G., Malbrain, M., Aoun, M., Garbino, J., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/503428 · Cited by 307
Pfaller, M. A., Diekema, D. J., & Sheehan, D. J. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.435-447.2006 · Cited by 295
Self-citationConcepts and Principles of Photodynamic Therapy as an Alternative Antifungal Discovery Platform
Dai, T., Fuchs, B. B., Coleman, J. J., Prates, R. A., Astrakas, C., St. Denis, T. G., Ribeiro, M. S., Mylonakis, E., Hamblin, M. R., & Tegos, G. P. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00120 · Cited by 295
Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies
Falagas, M. E., Apostolou, K. E., & Pappas, V. D. (2006) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-006-0159-2 · Cited by 294
Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database*
Shorr, A. F., Tabak, Y. P., Killian, A. D., Gupta, V., Liu, L. Z., & Kollef, M. H. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000239121.09533.09 · Cited by 286
McCarty, T. P., & Pappas, P. G. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.013 · Cited by 285
Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency
Drewniak, A., Gazendam, R. P., Tool, A. T. J., van Houdt, M., Jansen, M. H., van Hamme, J. L., van Leeuwen, E. M. M., Roos, D., Scalais, E., de Beaufort, C., et al. (2013) · Blood · doi:10.1182/blood-2012-08-450551 · Cited by 277
Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series
Delsing, C. E., Gresnigt, M. S., Leentjens, J., Preijers, F., Frager, F. A., Kox, M., Monneret, G., Venet, F., Bleeker-Rovers, C. P., van de Veerdonk, F. L., et al. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-166 · Cited by 271
Ahmad, S., & Alfouzan, W. (2021) · Microorganisms · doi:10.3390/microorganisms9040807 · Cited by 269
“Candidemia has an attributable mortality of 15–35% in adults and 10–15% in neonates [12].”
BackgroundCandidemia and Invasive Candidiasis
McCarty, T. P., White, C. M., & Pappas, P. G. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.007 · Cited by 260
Transcriptional regulation of carbohydrate metabolism in the human pathogen Candida albicans
Askew, C., Sellam, A., Epp, E., Hogues, H., Mullick, A., Nantel, A., & Whiteway, M. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000612 · Cited by 260
Laboratory diagnosis of invasive candidiasis.
Ellepola, A. N. B., & Morrison, C. J. (2005) · PubMed · Cited by 260
Candidemia and invasive candidiasis in adults: A narrative review
Antinori, S., Milazzo, L., Sollima, S., Galli, M., & Corbellino, M. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.06.029 · Cited by 257
Patients at High Risk of Invasive Fungal Infections: When and How to Treat
Rüping, M. J. G. T., Vehreschild, J. J., & Cornely, O. A. (2008) · Drugs · doi:10.2165/00003495-200868140-00002 · Cited by 253
Invasive candidiasis in the intensive care unit
Ostrosky-Zeichner, L., & Pappas, P. G. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000201897.78123.44 · Cited by 247
St. Denis, T. G., Dai, T., Izikson, L., Astrakas, C., Anderson, R. R., Hamblin, M. R., & Tegos, G. P. (2011) · Virulence · doi:10.4161/viru.2.6.17889 · Cited by 242
ALTERNATIVE CANDIDA ALBICANS LIFESTYLES: Growth on Surfaces
Kumamoto, C. A., & Vinces, M. D. (2005) · Annual Review of Microbiology · doi:10.1146/annurev.micro.59.030804.121034 · Cited by 237
Mice with Disseminated Candidiasis Die of Progressive Sepsis
Spellberg, B., Ibrahim, A. S., Edwards Jr., J. E., & Filler, S. G. (2005) · The Journal of Infectious Diseases · doi:10.1086/430952 · Cited by 230
Advances and challenges in management of invasive mycoses
Patterson, T. F. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67381-3 · Cited by 230
Pappas, P. G. (2006) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2006.07.004 · Cited by 227
Trends in the Epidemiology of Invasive Fungal Infections
Warnock, D. W. (2007) · Nippon Ishinkin Gakkai Zasshi · doi:10.3314/jjmm.48.1 · Cited by 226
Bougnoux, M.-E., Kac, G., Aegerter, P., d’Enfert, C., Fagon, J.-Y., & CandiRea Study Group (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0865-y · Cited by 224
“mortality of nosocomial candidemia were 61% and 49%, respectively [8], higher than the 38% observed over the”
ResultAzie, N., Neofytos, D., Pfaller, M., Meier-Kriesche, H.-U., Quan, S.-P., & Horn, D. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.06.012 · Cited by 222
Self-citationBench-to-bedside review: Candida infections in the intensive care unit
Méan, M., Marchetti, O., & Calandra, T. (2008) · Critical Care · doi:10.1186/cc6212 · Cited by 217
Piarroux, R., Grenouillet, F., Balvay, P., Tran, V., Blasco, G., Millon, L., & Boillot, A. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000147726.62304.7f · Cited by 216
Bruno, V. M., Wang, Z., Marjani, S. L., Euskirchen, G. M., Martin, J., Sherlock, G., & Snyder, M. (2010) · Genome Research · doi:10.1101/gr.109553.110 · Cited by 211
Candida albicans: A Model Organism for Studying Fungal Pathogens
Kabir, M. A., Hussain, M. A., & Ahmad, Z. (2012) · ISRN Microbiology · doi:10.5402/2012/538694 · Cited by 211
Biofilm formation in clinical Candida isolates and its association with virulence
Hasan, F., Xess, I., Wang, X., Jain, N., & Fries, B. C. (2009) · Microbes and Infection · doi:10.1016/j.micinf.2009.04.018 · Cited by 206
Recognition and Blocking of Innate Immunity Cells by Candida albicans Chitin
Mora-Montes, H. M., Netea, M. G., Ferwerda, G., Lenardon, M. D., Brown, G. D., Mistry, A. R., Kullberg, B. J., O'Callaghan, C. A., Sheth, C. C., Odds, F. C., et al. (2011) · Infection and Immunity · doi:10.1128/iai.01282-10 · Cited by 204
Antimicrobial therapy for patients with severe sepsis and septic shock: An evidence-based review
Bochud, P.-Y., Bonten, M., Marchetti, O., & Calandra, T. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000143118.41100.14 · Cited by 201
Clark, T. A., Slavinski, S. A., Morgan, J., Lott, T., Arthington-Skaggs, B. A., Brandt, M. E., Webb, R. M., Currier, M., Flowers, R. H., Fridkin, S. K., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4468-4472.2004 · Cited by 200
Mukaremera, L., Lee, K. K., Mora-Montes, H. M., & Gow, N. A. R. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00629 · Cited by 199
Self-citationPukkila-Worley, R., Peleg, A. Y., Tampakakis, E., & Mylonakis, E. (2009) · Eukaryotic Cell · doi:10.1128/ec.00163-09 · Cited by 192
Dimopoulos, G., Ntziora, F., Rachiotis, G., Armaganidis, A., & Falagas, M. E. (2008) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181607262 · Cited by 189
Prokaryote–eukaryote interactions identified by using Caenorhabditis elegans
Peleg, A. Y., Tampakakis, E., Fuchs, B. B., Eliopoulos, G. M., Moellering, R. C., & Mylonakis, E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805048105 · Cited by 188
Risk factors for candidemia: a prospective matched case-control study
FUNGINOS, T., Poissy, J., Groups, A. F. S., Damonti, L., Bignon, A., Khanna, N., Von Kietzell, M., Boggian, K., Neofytos, D., Vuotto, F., et al. (2020) · Critical Care · doi:10.1186/s13054-020-2766-1 · Cited by 188
Comparison of echinocandin antifungals
Eschenauer, G., DePestel, D. D., & Carver, P. L. (2007) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2007.3.1.71 · Cited by 186
Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?
Charlier, C., Hart, E., Lefort, A., Ribaud, P., Dromer, F., Denning, D. W., & Lortholary, O. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki473 · Cited by 184
Treatment-related risk factors for hospital mortality in Candida bloodstream infections
Labelle, A. J., Micek, S. T., Roubinian, N., & Kollef, M. H. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e31818b3477 · Cited by 181
Gazendam, R. P., van Hamme, J. L., Tool, A. T. J., van Houdt, M., Verkuijlen, P. J. J. H., Herbst, M., Liese, J. G., van de Veerdonk, F. L., Roos, D., van den Berg, T. K., et al. (2014) · Blood · doi:10.1182/blood-2014-01-551473 · Cited by 181
Spellberg, B. J., Ibrahim, A. S., Avanesian, V., Fu, Y., Myers, C., Phan, Q. T., Filler, S. G., Yeaman, M. R., & Edwards, Jr. (2006) · The Journal of Infectious Diseases · doi:10.1086/504691 · Cited by 180
Rabbit Model of Candida albicans Biofilm Infection: Liposomal Amphotericin B Antifungal Lock Therapy
Schinabeck, M. K., Long, L. A., Hossain, M. A., Chandra, J., Mukherjee, P. K., Mohamed, S., & Ghannoum, M. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1727-1732.2004 · Cited by 180
Krause, D. S., Reinhardt, J., Vazquez, J. A., Reboli, A., Goldstein, B. P., Wible, M., & Henkel, T. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2021-2024.2004 · Cited by 179
Contributions of the Biofilm Matrix to Candida Pathogenesis
Nett, J. E., & Andes, D. R. (2020) · Journal of Fungi · doi:10.3390/jof6010021 · Cited by 179
Diagnostic Issues, Clinical Characteristics, and Outcomes for Patients with Fungemia
Arendrup, M. C., Sulim, S., Holm, A., Nielsen, L., Nielsen, S. D., Knudsen, J. D., Drenck, N. E., Christensen, J. J., & Johansen, H. K. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00179-11 · Cited by 178
Chen, S. C. A., & Sorrell, T. C. (2007) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2007.tb01313.x · Cited by 175
Ortega, M., Marco, F., Soriano, À., Almela, M., Martínez, J. A., López, J. D. S., Pitart, C., & Mensa, J. (2011) · Journal of Hospital Infection · doi:10.1016/j.jhin.2010.09.026 · Cited by 175
Active Surveillance of Candidemia, Australia
Chen, S., Slavin, M., Nguyen, Q., Marriott, D., Playford, E. G., Ellis, D., Sorrell, T., & Study, T. A. C. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1210.060389 · Cited by 174
Guery, B. P., Arendrup, M. C., Auzinger, G., Azoulay, É., Borges Sá, M., Johnson, E. M., Müller, E., Putensen, C., Rotstein, C., Sganga, G., et al. (2009) · Intensive Care Medicine · doi:10.1007/s00134-008-1338-7 · Cited by 173
“Attributable mortality of candidiasis was evaluated retrospectively between 1997 and 2001 in 108 matched pairs [12], the crude mortality among case patients was 61% compared with 12% in”
ResultCandidemia in Norway (1991 to 2003): Results from a Nationwide Study
Sandven, P., Bevanger, L., Digranes, A., Haukland, H. H., Mannsåker, T., Gaustad, P., & the Norwegian Yeast Study Group (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00029-06 · Cited by 173
From Jekyll to Hyde: The Yeast–Hyphal Transition of Candida albicans
Chow, E. W. L., Pang, L. M., & Wang, Y. (2021) · Pathogens · doi:10.3390/pathogens10070859 · Cited by 173
Metadata
- Authors
- Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D.
- Affiliations
- University of Iowa Hospitals and Clinics (US)
- University of Iowa (US)
- Corresponding author
- Diekema, D.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-11-01
- Volume
- 37
- Issue
- 9
- Pages
- 1172-1177
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2118236446
- Cited by
- 1,140
- References
- 37
- Citations by year
- 2026: 14 · 2025: 19 · 2024: 22 · 2023: 30 · 2022: 35 · 2021: 34 · 2020: 35 · 2019: 38 · 2018: 35 · 2017: 51 · 2016: 41 · 2015: 59 · 2014: 74 · 2013: 76 · 2012: 60
- FWCI
- 26.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Nosocomial Infections in ICU
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Keywords
- nosocomial candidemia, attributable mortality, candidemia, mortality, matched case-control comparison, underlying disease, risk factors, nosocomial infections
- MeSH terms
- Age Factors, Antifungal Agents, Candida, Candidiasis, Cross Infection, Female, Humans, Length of Stay, Male, Microbial Sensitivity Tests, Middle Aged, Retrospective Studies, Sex Factors, Cohort Studies, Fluconazole, Survival Rate, Fungemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.